Molecular Health Strengthens U.S. Based Executive Management Team

Press Releases

Molecular Health Strengthens U.S. Based Executive Management Team

Appoints Gerry Sheridan as Chief Financial Officer


Appoints Dr. Les Paul as Chief Medical Officer


Boston, MA and Heidelberg, Germany – July 21, 2016 – Molecular Health, a leader in precision medicine technology focused on commercializing products utilizing its proprietary Dataome™ technology platform, today announced it has strengthened its leadership team with the appointment of two U.S.-based executives. Gerry Sheridan will serve as Chief Financial Officer and Dr. Les Paul as Chief Medical Officer. Mr. Sheridan and Dr. Paul will be based in the Company’s U.S. headquarters in Boston to facilitate the Company’s expansion into the U.S. commercial markets and building of an expanded U.S. operational infrastructure.  


Molecular Health Executive Chairman Friedrich von Bohlen commented, “The addition of Gerry and Les to our executive team is an exciting and critical step in building our U.S. commercial and operational infrastructure to support the continued commercial ramp of the GUIDE platform. Both bring substantial experience from commercial stage healthcare and oncology-focused companies. Their combined financial, medical and operational expertise together with their longstanding relationships with stakeholders across the U.S., make both Gerry and Les the optimal candidates to help deliver GUIDE, our fully automated cloud-based clinical decision support software, to the growing U.S. market.”


Mr. Sheridan said, “It is a tremendous opportunity to join Molecular Health at this juncture in their corporate development. Their existing global footprint, growth potential and commitment to bringing their revolutionary technology to such a large healthcare constituency make it an exciting time to join such a dynamic team. ”


Dr. Paul added, “GUIDE is uniquely positioned to systematically lead physicians and their patients to the best possible treatment outcomes.  Information sciences as a support tool to help drive informed treatment decisions based upon the latest and most relevant literature, discoveries and knowledge is a tremendous offering to the medical community.  I feel privileged to join the Molecular Health team and am excited to help broaden the market adoption of this technology. I am confident it will make a lasting impact on patients’ lives.”


Mr. Sheridan brings to Molecular Health over 25 years of international financial, operating and consulting experience and extensive knowledge of U.S. and European markets. Most recently, Gerry served as CFO of Seno Medical Instruments, an oncologic medical device company, where he led their most recent Series C funding round of $80 Million as the company began marketing and commercializing its device. Prior to his experience at Seno, Gerry was CFO of GDC Technics, an aerospace design firm. Mr. Sheridan graduated from University College Dublin in Ireland, is a qualified Chartered Accountant, a Certified Public Accountant and a member of the American Institute of Certified Public Accountants.


Dr. Paul joins Molecular Health following a lengthy career in medicine and in business. He has served as Chief Medical Officer at Caris Life Sciences; SVP, Global Medical Affairs at Intermune, VP, U.S. Medical Affairs at Novartis, VP, U.S. Medical Affairs at AstraZeneca R&D, VP, Medical Policy / Programs and Medical Affairs at MedCo Health Solutions before it was acquired by Express Scripts in 2012, and most recently he served as Principal at Tradewind Life Science Advisors. He has extensive experience in the pharmaceutical industry and in leading integrated U.S. and Global Medical Affairs teams in multiple therapeutic areas including precision cancer therapy and diagnostics. He has also been responsible for the medical aspects of product commercialization, medical policy, publications and scientific communication, and research.  Dr. Paul received his Doctor of Medicine Degree from the University of Illinois and his Masters in Preventative Medicine and Administrative Medicine from the University of Wisconsin-Madison. He is also Board Certified in Internal Medicine & Pulmonary Disease from the American Board of Internal Medicine.


About Molecular Health

Molecular Health is a leading precision medicine technology company that leverages its proprietary Dataome™ technology platform to provide the world’s most comprehensive and disruptive healthcare decision engine. The Dataome™ platform continuously retrieves the latest clinical, pharmaceutical, biomarker, and disease information from around the world and contextualizes it in a way to provide a tool that yields unparalleled perspective, actionable treatment and clinical direction, and deeper insights into the complex and growing world of data.


To learn more, please visit:


Investors U.S.

Nick Laudico

The Ruth Group

(646) 536-7030

Media U.S.

Kirsten Thomas / Chris Hippolyte

The Ruth Group

+1 508-280-6592 / +1 646-536-7023 /

Media & Investors EMEA

Dr. Ludger Wess / Ines-Regina Buth


+49 40 88 16 59 64/ +49 30 23 63 27 68





Other Articles

In der Ausgabe Management & Krankenhaus 9/2016 äußerts Geschäftsführer von Molecular Health, Dr. Stephan Brock  interviewt.

Monday, October 24th

apotheke adhoc schreibt über Molecular Health und neue Diagnoseverfahren:

Die Krebstherapie steht nach Einschätzung von Wissenschaftlern, Ärzten und Herstellern in den kommenden Jahren vor einer Revolution. Neue Diagnoseverfahren und darauf basierende Therapien versprechen einen Durchbruch, der sogar die Heilung von Krebs zur Realität oder den Krebs zumindest zu einer beherrschbaren Volkskrankheit machen könnte. Gentechnik und Big Data spielen dabei die entscheidende Rolle

Monday, September 19th

Gerry Sheridan zum Chief Financial Officer und Dr. Les Paul zum Chief Medical Officer ernannt

Monday, August 15th

Bundesforschungsministerin Johanna Wanka hat am 16. November 2015 auf der internationalen Messe MEDICA das neue Förderkonzept „Medizininformatik“ erstmals einer breiten Fachöffentlichkeit vorgestellt. Ziel des Förderkonzepts ist es, die Patientenversorgung und die Forschungsmöglichkeiten durch innovative IT-Systeme zu verbessern. Diese IT-Systeme sollen die Nutzung von Daten aus Krankenversorgung, biomedizinischer und klinischer Forschung über die Grenzen von Institutionen und Standorten hinweg ermöglichen.

Friday, July 29th

Auf Einladung des Bayerischen Staatsministeriums für Wirtschaft und Medien, Energie und Technologie hat Friedrich von Bohlen, CEO von Molecular Health, am 30.06.2016 einen Impulsvortrag zum Thema „Precision Medicine“ im Rahmen der Veranstaltung „Digitalisierung der Medizin in Bayern – Fokus klinische Patientendaten“ gegeben.
Es waren hochrangige Vertreter aus Klinik, Forschung, Politik und Wirtschaft anwesend, um praktische Herausforderungen und notwendige Maßnahmen zu diskutieren und formulieren, um die Digitalisierung der Medizin in Bayern voranzutreiben.

Friday, July 29th

Mit einem Vortrag zur „Evidenzbasierten molekularen Dateninterpretation in der personalisierten Tumortherapie“ von Dr. Sandra Morandell präsentierte sich Molecular Health auf der diesjährigen IIR Spital 2016 in Vösendorf bei Wien und stieß auf großes Interesse bei den 250 Teilnehmern und den Gesprächspartnern der österreichischen onkologischen Community.

Friday, July 29th

Molecular Health war mit einem Fachexperten als Referent zu Gast bei der Podiumsdiskussion des diesjährigen ApoForums „Digital Health – Disruption oder Evolution der Gesundheitsversorgung?“ am 29. Juni in Düsseldorf. Dr. Mathias Göschl (Vice President, Content) diskutierte mit Führungskräften der Gesundheitsbranche, Ärzten, Apothekern und Experten aus Politik und Wissenschaft.

Friday, July 29th

Molecular Health will no longer provide its end-to-end cancer diagnostic medical services in the US and thus will terminate processing patient cases effective August 19, 2016. In order to honor our turn-around time commitments, we will not be accepting any new patient cases after July 29, 2016.


In the future, Molecular Health will be focusing its efforts to further develop its information solutions for clinical decision support in oncology and drug safety, MH Guide and MH Effect, and its Dataome technology platform.


Wednesday, July 27th

Results published today in Cancer Cell validate new diagnostic biomarker for reducing adverse events and improving outcomes of cancer patients with anemia

Findings enable potential patient stratification for tailored treatment

Friday, June 17th

Enrollment Now Open for Early Access Program (EAP) Set to Launch in November 2015

Cambridge, MA – October 5, 2015 – Molecular Health, a leader in cloud-based healthcare decision support technology to optimize the selection of therapies for improved patient outcomes, today announced that it will initiate an early access program (EAP) offering its SafetyMAP™ software to pharmaceutical companies and clinical professionals involved in drug safety starting in November 2015.

Friday, June 17th

The "Corporate Oncology Program for Employees" with Molecular Health

Schwalbach/Heidelberg - September 23, 2015 - As of September 1, 2015, EMC in Germany will be joining forces with Molecular Health to launch a Corporate Oncology Program for Employees (COPE). If an EMC employee or the spouse, partner, or child of an EMC employee are diagnosed with cancer, the program will fund an analysis of the patient's tumor genome so that the most promising treatment options can be identified.

Friday, June 17th

Cambridge, MA – September 9, 2015 – Molecular Health has entered into a commercial license to provide the FDA with use of its SafetyMAP™ software - formerly known as Molecular Analysis of Side Effect information (MASE™), to provide a comprehensive and dynamic analytical solution for the detection and molecular analysis of drug-induced adverse events for all marketed drugs and for predicting safety issues of new drug candidates.

Friday, June 17th

Germline biomarkers predicted drug toxicity: impact on clinical routine

June 30, 2015, Heidelberg/Cambridge, MA. A core tenet of precision medicine is that predictive biomarkers can enhance therapeutic decision-making. In a new pilot study, scientists at Molecular Health analyzed a randomly selected set of 250 patients with solid tumors and detected predictive biomarkers in more than 85% of tumors.

Friday, June 17th

Many tests for predictive biomarkers in tumors focus on selected known mutations

June 29, 2015. Heidelberg / Cambridge, MA. Many tests for predictive biomarkers in tumors focus on selected known mutations or regions (e.g., hotspot panels). In a new study, scientists at Molecular Health examined the rates of secondary mutations in known biomarker genes and their potential impact on the diagnostic reliability of specific single-nucleotide variant (SNV) biomarker testing.

Friday, June 17th

June 4, 2015

Cambridge, MA, Houston, TX – Molecular Health signed an agreement with TestAnalytika to be its preferred distributor in the Latin American region at the 2015 ASCO Annual Meeting.  TestAnalytika will begin to market and distribute Molecular Health’s cancer treatment decision support product, TreatmentMAP™, to patients, physicians, hospitals, laboratories, cancer centers and insurers in Latin America later this year.

Friday, June 17th

The Guardian Research Network and Molecular Health will Provide Cancer Patients with Personalized Clinical Decision Support

CAMBRIDGE, Massachusetts and SPARTANBURG, South Carolina, May 29, 2015

The Guardian Research Network and Molecular Health have announced a collaboration designed to provide therapeutic clinical trial access and molecular diagnostic decision support to the majority of cancer patients living in U.S. communities.

Friday, June 17th

Category at SAPPHIRE® NOW Conference

May 8, 2015 Cambridge, MA / Heidelberg, Germany - Molecular Health today announced it has won an SAP HANA® Innovation Award in the category Technology Trailblazer - Business Application. The awards presented by SAP SE (NYSE: SAP) recognize the extraordinary ways that customers are using the SAP HANA platform to transform their business and society. 

Molecular Health received its award at a ceremony hosted by SAP at SAPPHIRE® NOW and the ASUG Annual Conference held May 5-7 in Orlando, Fla.

Friday, June 17th

Addresses unmet need in treatment of millions of cancer patients

April 27, 2015 Cambridge, MA / Heidelberg, Germany -- Molecular Health announced today it has been granted a patent in Europe entitled “Tissue Protective Erythropoietin Receptor”. This latest patent supports Molecular Health’s discovery that EPHB4 is a novel receptor for Erythropoietin (EPO), where EPHB4 binds to EPO and promotes tumor growth. 

Friday, June 17th
  • GATC Biotech to play an essential role in the commercialisation of TreatmentMAP™
  • Significantly increased access to the first registered medical device for personalised cancer medicine in Europe
  • GATC Biotech expands the market reach and opportunities of its Diagnostic Solutions division

Constance, Germany, 21 April 2015: GATC Biotech, provider of innovative, high quality DNA and RNA sequencing solutions to the pharmaceutical and diagnostics markets, announced today that it has signed a commercial agreement with Molecular Health.

Friday, June 17th

HEIDELBERG, Germany & THE WOODLANDS, Texas--(BUSINESS WIRE)--Molecular Health announced today that its chief innovation officer, David Jackson, Ph.D., will speak at this year’s 

Friday, June 17th